HPV Immunotherapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 3924
Special Issue Editor
Interests: inflammation; resolution; resolvins; lipoxins; oncoviruses; hpv; autophagy; neutrophils; macrophages; cystic fibrosis; chronic inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Infection with high-risk human papilloma viruses (HPV) is the causative agent of cervical cancer and is associated with other anogenital malignancies and head and neck cancers. Novel therapeutic approaches to control HPV cancers are of wide interest since, despite the implementation of an effective vaccination program, HPV cancer burden is still very high.
Immunotherapy aimed at strengthening the host immune system response against tumor cells has shown promise in HPV malignancies. However, benefits are limited for some patients, urging more efforts in this area.
The focus of this Research Topic is to collect articles, reviews or case reports covering different aspects of HPV cancers and immunology that shed light on potential innovative therapeutic options, such as, but not limited to:
- Immunotherapy and delivery systems;
- Tumor/immune system crosstalk;
- Strategies to re-educate immune cells;
- Biomarkers to follow and predict response to immune therapies.
Dr. Domenico Mattoscio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HPV cancers
- Cervical cancer
- Head and neck cancer
- HPV vaccines
- HPV immunotherapy
- Immune checkpoint inhibitors
- T-cell transfer therapy
- Monoclonal antibodies
- Immune system modulators
- Immune cells
- Innate and adaptive immune response
- Biomarkers
- Tumor-host interaction
- Tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
